Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate

Vaccine

Volumn 30, Issue 10, 2012, Pages 1807-1812

  Tachibana, Mayumi ^a   Sato, Chiho ^a   Otsuki, Hitoshi ^b   Sattabongkot, Jetsumon ^c,f   Kaneko, Osamu ^d   Torii, Motomi ^a,e   Tsuboi, Takafumi ^e  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d NAGASAKI UNIVERSITY   (Japan)

^e EHIME UNIVERSITY   (Japan)

^f MAHIDOL UNIVERSITY   (Thailand)

Author keywords

DNA vaccine; Gametocyte; Malaria; Plasmodium vivax; Pvs230; Transmission blocking vaccine

Indexed keywords

BACTERIAL PROTEIN; PVS230 PROTEIN; UNCLASSIFIED DRUG; VAXFECTIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL TRANSMISSION; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; GAMETOCYTE; IMMUNITY; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CULICIDAE; DNA, PROTOZOAN; FEMALE; HUMANS; IMMUNE SERA; MALARIA VACCINES; MALARIA, VIVAX; MICE; MICE, INBRED DBA; PLASMIDS; PLASMODIUM VIVAX; POLYMORPHISM, GENETIC;

EID: 84857458089     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.003     Document Type: Article

References (25)

1. WHO World Malaria Report 2010 2010, WHO Press, Geneva, Switzerland.
2. Price R.N., Tjitra E., Guerra C.A., Yeung S., White N.J., Anstey N.M. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007, 77:79-87.
3. Mueller I., Galinski M.R., Baird J.K., Carlton J.M., Kochar D.K., Alonso P.L., et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 2009, 9:555-566.
4. Kaneko A., Taleo G., Kalkoa M., Yamar S., Kobayakawa T., Bjorkman A. Malaria eradication on islands. Lancet 2000, 356:1560-1564.
5. Arevalo-Herrera M., Chitnis C., Herrera S. Current status of Plasmodium vivax vaccine. Hum Vaccin 2010, 6:124-132.
6. Herrera S., Bonelo A., Perlaza B.L., Fernandez O.L., Victoria L., Lenis A.M., et al. Safety and elicitation of humoral and cellular responses in Colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 2005, 73:3-9.
7. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23:3131-3138.
8. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with Montanide ISA 51. PLoS ONE 2008, 3:e2636.
9. Kaslow D.C., Quakyi I.A., Syin C., Raum M.G., Keister D.B., Coligan J.E., et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988, 333:74-76.
10. Tsuboi T., Kaslow D.C., Gozar M.M., Tachibana M., Cao Y.M., Torii M. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 1998, 4:772-782.
11. Williamson K.C., Criscio M.D., Kaslow D.C. Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230. Mol Biochem Parasitol 1993, 58:355-358.
12. Tachibana M., Wu Y., Iriko H., Muratova O., MacDonald N.J., Sattabongkot J., et al. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin Vaccine Immunol 2011, 18:1343-1350.
13. van Dijk M.R., van Schaijk B.C., Khan S.M., van Dooren M.W., Ramesar J., Kaczanowski S., et al. Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility. PLoS Pathog 2010, 6:e1000853.
14. Carter R., Coulson A., Bhatti S., Taylor B.J., Elliott J.F. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Mol Biochem Parasitol 1995, 71:203-210.
15. Gerloff D.L., Creasey A., Maslau S., Carter R. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. Proc Natl Acad Sci U S A 2005, 102:13598-13603.
16. Williamson K.C., Keister D.B., Muratova O., Kaslow D.C. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol 1995, 75:33-42.
17. Doi M., Tanabe K., Tachibana S., Hamai M., Tachibana M., Mita T., et al. Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax. Vaccine 2011, 29:4308-4315.
18. Han E.T., Watanabe R., Sattabongkot J., Khuntirat B., Sirichaisinthop J., Iriko H., et al. Detection of four Plasmodium species by genus- and species-specific loop-mediated isothermal amplification for clinical diagnosis. J Clin Microbiol 2007, 45:2521-2528.
19. Hartikka J., Bozoukova V., Ferrari M., Sukhu L., Enas J., Sawdey M., et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001, 19:1911-1923.
20. Sullivan S.M., Doukas J., Hartikka J., Smith L., Rolland A. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv 2010, 7:1433-1446.
21. Collins W.E., Contacos P.G., Krotoski W.A., Howard W.A. Transmission of four Central American strains of Plasmodium vivax from monkey to man. J Parasitol 1972, 58:332-335.
22. Read D., Lensen A.H., Begarnie S., Haley S., Raza A., Carter R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol 1994, 16:511-519.
23. Lobo C.A., Dhar R., Kumar N. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 1999, 67:1688-1693.
24. Kongkasuriyachai D., Bartels-Andrews L., Stowers A., Collins W.E., Sullivan J., Sattabongkot J., et al. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 2004, 22:3205-3213.
25. Fanning S.L., Czesny B., Sedegah M., Carucci D.J., van Gemert G.J., Eling W., et al. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230. Vaccine 2003, 21:3228-3235.